The effects of menopause on the quality of life and long-term outcomes of transobturator tape treatment in women with stress urinary incontinence

Mehmet Oguz Sahin 1, Volkan Sen 1, Bora Irer 2, Guner Yildiz 3

1 Department of Urology, Manisa State Hospital, Manisa, Turkey; 2 Department of Urology, Izmir Metropolitan Municipality Esrefpasa Hospital, Izmir, Turkey; 3 Department of Urology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey

ABSTRACT

Purpose: We aimed to investigate the effects of menopause on long-term outcomes of transobturator tape (TOT) surgery.

Materials and Methods: Patients who underwent TOT surgery were evaluated under two groups as postmenopausal and premenopausal. The International Consultation on Incontinence short-form questionnaire (ICIQ-SF), Incontinence Impact Questionnaire (IIQ-7) and Urogenital Distress Inventory-Short Form (UDI-6) questionnaires were completed by the patients at the 1st and 5th-year follow-up sessions. Patients with a postoperative UDI-6 and IIQ-7 score of <10 were considered as cured, those with lower postoperative scores compared to the preoperative period were regarded as improved, and the cases that had higher postoperative scores than preoperative values were interpreted as TOT failure. The TOT success rates were compared between the results obtained from UDI-6 and IIQ-7.

Results: A total of 109 patients were included in the study (53 postmenopausal and 56 premenopausal). We contacted with 90 (48 premenopausal and 42 postmenopausal) women at 1st year control and 80 (44 premenopausal and 36 postmenopausal) women at 5th year control. There was a significant improvement in all of three questionnaires between the preoperative and post-operative 1st year control (ICIQ-SF: 15.5±2.5 vs. 1.8±4.3, p <0.001; IIQ-7: 68.9±9.8 vs. 2.75±15.2, p <0.001; UDI-6: 27.1±11.1 vs. 6.0±14.6, p <0.001) and the preoperative and post-operative 5th year control (ICIQ-SF: 15.5±2.5 vs. 3.1±5.3, p <0.001; IIQ-7: 68.9±9.8 vs. 9.6±26.7, p <0.001; UDI-6: 27.1±11.1 vs. 5.1±10.0, p <0.001). When we compared the premenopausal and postmenopausal patients in terms of recurrent urinary tract infection (UTI); 5 (12%) patients had recurrent UTI in postmenopausal group but no patients had recurrent UTI in premenopausal group at 1st year follow-up (p=0.039) and similarly the same 5 (13.9%) patients in follow-up had recurrent UTI in postmenopausal group but no patients had recurrent UTI in premenopausal group at 5th year follow-up (p=0.045). There were no significant differences between the premenopausal and postmenopausal patients in terms of TOT success rates at 1st and 5th year control, evaluated with UDI-6 (1st year: p=0.198 and 5th year: p=0.687) and IIQ-7 (1st year: p=0.489 and 5th year: p=0.608) questionnaires.

Conclusions: Transobturator tape surgery is an effective and reliable method according to the long-term outcomes reported in this paper. In the current study, we determined that the TOT success rates were not affected by the presence of menopause.
INTRODUCTION

Urinary incontinence (UI) has been defined as involuntary urine loss by the International Continence Society (ICS) (1). Risk factors for UI include age, obesity and excess adipose tissue, parity, pregnancy, hormone replacement therapy for menopause, ethnicity and race, hysterectomy, dietary factors, socioeconomic status, smoking, physical activity, and comorbidities (diabetes, urinary tract infection (UTI), cognitive disorder, ischemic heart disease, physical disorders, and depression) (1, 2). Stress urinary incontinence (SUI), one of the most common types of UI, occurs when the bladder pressure exceeds urethral resistance due to increased abdominal pressure in exercise, sneezing, or coughing, and its prevalence ranges from 4 to 35% in the literature (3, 4). Transobturator tape (TOT) treatment was first described in 2001 and presents as an alternative to the mid-urethral sling technique, in which the synthetic mesh is inserted through the obturator foramen (5).

With menopause and advancing age, all urogynecologic disorders have been shown to increase. Menopause results in the reduction of the maximal urethral closure pressure. At the same time, bladder capacity and detrusor pressure during voiding is significantly decreased in the elderly population (6). On the other hand, estrogen receptors have been identified along the pelvic floor trigone and uterosacral ligaments including the urethra, vagina and bladder, and estrogen loss was often associated with urogenital atrophy and urinary symptoms after menopause (7). Stress urinary incontinence is more commonly seen among postmenopausal patients, and studies in the literature have reported different results in term of the success and complication rates of TOT surgery in premenopausal and postmenopausal patients (8, 9).

In this study, we aimed to investigate the effects of menopause on the long-term outcomes of the TOT operation, which is defined as a minimally invasive technique.

MATERIALS AND METHODS

After obtaining the approval of the local ethics committee, patients who underwent suburethral vaginal TOT surgery due to SUI in our urology clinic between January 2008 and June 2013 were retrospectively reviewed. Patients were evaluated under two groups as postmenopausal and premenopausal before the TOT operation. Lifestyle changes including weight loss and pelvic muscle exercises were offered before and after the TOT surgery. Demographic characteristics of the patients, International Consultation on Incontinence short-form questionnaire (ICIQ-SF), Urogenital Distress Inventory-Short Form (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) questionnaire results, examination findings, stress test (MMK: Marshall-Marchetti-Krantz), Q-tip test, operation results, and complications were noted. Patients who previously had surgery for UI or pelvic organ prolapse, those having a marked neurological disease, urgency urinary incontinence (UUI), or cystocele or rectocele at the degree that would require surgical repair, and those who were using medication that made them prone to bleeding and the patients who were premenopausal before the surgery and then became menopausal during the time interval of study were excluded from the study. None of the patients with menopause took any hormonal therapy in their follow-up. TOT operation decision was scheduled for patients that had no preoperative pathology according to the urodynamic testing, a Q-tip test result of >30 degrees, and a positive stress test result. All operations were performed using the outside-in method under spinal anesthesia. Polypropylene mesh (Uni-tape T-Promedon®) was used as the TOT material during the operation. Cystoscopy was not routinely performed to all patients.

Urogynecologic examinations were performed on the patients. Q-tip angle, MMK test, operation success, and per-operative complications were recorded. The Turkish versions of the ICIQ-SF, IIQ-7 and UDI-6 questionnaires, which had been previously validated, were completed by the patients again at the first- and fifth-year follow-up sessions (10, 11). The outcomes of the operation were classified according to the subjective evaluations of the patients through the questionnaires: Patients with a postoperative UDI-6 and IIQ-7 score of <10 were considered as cured, those with lower postoperative scores compared to
the preoperative period were regarded as improved, and the cases that had higher postoperative scores than preoperative values were interpreted as TOT failure (12). The overall success rate of TOT was defined as sum of the cure and improvement rates. TOT success rates were compared between the groups at 1st and 5th year outcomes.

Data were analyzed using the Statistical Package for Social Sciences (SPSS, Inc., Chicago IL) version 22 and expressed as mean±standard deviation, number (n) and percentage (%) values. In the comparison of categorical variables between the groups, the X² test and Student’s t-test were employed to compare continuous variables. A p value of 0.05 was considered to be statistically significant.

RESULTS

A total of 109 patients were included in the study and their mean age was 52.4±10.1 (27-76) years. There were 53 postmenopausal (48.6%) and 56 premenopausal (51.4%) women. The mean body mass index (BMI) of the patients was 26.2±4.0 (20.2-34.4) kg/m². The mean Q-tip test angle was 57.0±17.1 (30-90) degrees and the mean follow-up period was 74.4±46.2 (1-138) months. The mean operation time was 29.7±9.7 (12-60) minutes, and the mean hospitalization time was 1.2±0.5 (1-3) days. For all patients, the cough (MMK) test was positive and UUI was negative. We contacted with 90 (48 premenopausal and 42 postmenopausal) women at 1st year control and 80 (44 premenopausal and 36 postmenopausal) women at 5th year control (Figure-1).

The overall success rate of TOT procedure was detected as 93.3% at 1st year follow-up and 88.8% at 5th year follow-up according to both IIQ-7 and UDI-6 questionnaires. There was no significant difference between the success rates of premenopausal and postmenopausal patients at 1st year follow-up (93.7% vs. 92.9%, p=0.865) and 5th year follow-up (90.9% vs. 86.1%, p=0.499) (Table-1). The cure rates were also similar between the premenopausal and postmenopausal patients

Figure 1 - The first-year and fifth-year distribution of the patients that underwent TOT surgery.

TOT procedure was performed to 109 women
Postmenopausal:53 Premenopausal:56

Unable to contact 19 patients

First-year follow-up: 90 patients
Postmenopausal:42 Premenopausal: 48

Unable to contact 10 patients

Fifth-year follow-up: 80 patients
Postmenopausal: 36 Premenopausal: 44
The effects of menopause on TOT surgery

According to IIQ-7 (83.3% vs. 78.6%, p=0.821) and UDI-6 (70.8% vs. 54.8%, p=0.648) at 1st year; IIQ-7 (75.0% vs. 69.4%, p=0.485) and UDI-6 (75.0% vs. 69.4%, p=0.485) at 5th year follow-up (Table-1).

When we compared the premenopausal and postmenopausal patients in terms of recurrent urinary tract infection (UTI); 5 (12%) patients had recurrent UTI in postmenopausal group but no patients had recurrent UTI in premenopausal group at 1st year follow-up (p=0.039) and similarly the same 5 (13.9%) patients on follow-up had recurrent UTI in postmenopausal group but no patients had recurrent UTI in premenopausal group at 5th year follow-up (p=0.045). No new recurrent UTI was added between 1st and 5th year follow-up.

While 22 (20.2%) women had urgency in the preoperative period, the postoperative new urgency was observed in three patients (3.3%) in 1st year and 11 patients (13.8%) in 5th year. In addition, no UUI was found in the preoperative period whereas UUI was observed to newly develop in five patients (5.6%) in the first-year and 11 (13.8%) patients in the fifth-year follow-up.

There was a significant improvement in all of the three questionnaires between the preoperative and post-operative 1st year control (ICIQ-SF: 15.5±2.5 vs. 1.8±4.3, p <0.001; IIQ-7: 68.9±9.8 vs. 2.75±15.2, p <0.001; UDI-6: 27.1±11.1 vs. 6.0±14.6, p <0.001) and the preoperative and postoperative 5th year control (ICIQ-SF: 15.5±2.5 vs. 3.1±5.3, p <0.001; IIQ-7: 68.9±9.8 vs. 9.6±26.7, p <0.001; UDI-6: 27.1±11.1 vs. 5.1±10.0, p <0.001). The preoperative Q-tip test angles were significantly lower in the postoperative 1st and 5th years (p <0.001), which is an indication of the efficacy and permanence of the positive outcomes of the operation (Table-2).

Table 1 - Comparison of the cure and success rates of postmenopausal and premenopausal groups in terms of the first-year and fifth-year outcomes according to IIQ7 and UDI-6.

|                  | Postoperative 1st year | Postoperative 5th year |
|------------------|------------------------|------------------------|
|                  | (90 patients; 48 premenopausal; 42 postmenopausal) | (80 patients; 44 premenopausal; 36 postmenopausal) |
| IIQ-7            |                        |                        |
| Failure          | 6 (6.7%)               | 9 (11.2%)              |
| Cure             | 73 (81.1%)             | 58 (72.5%)             |
| Improvement      | 11 (12.2%)             | 13 (16.3%)             |
| Success          | 84 (93.3%)             | 71 (86.8%)             |
| P*               |                        | 0.821                  |
| P**              |                        | 0.485                  |
| P                 |                        |                        |
| Postmenopausal   |                        |                        |
| Failure          | 3 (7.1%)               | 6 (14.3%)              |
| Cure             | 33 (78.6%)             | 25 (69.4%)             |
| Improvement      | 6 (14.3%)              | 6 (16.7%)              |
| Success          | 6 (12.2%)              | 31 (86.1%)             |
| Premenopausal    |                        |                        |
| Failure          | 3 (6.3%)               | 5 (10.4%)              |
| Cure             | 40 (83.3%)             | 45 (93.7%)             |
| Improvement      | 0.821                  | 0.865                  |
| Success          | 13 (16.3%)             | 33 (75.0%)             |
| P*               |                        |                        |
| P**              |                        |                        |
| UDI-6            |                        |                        |
| Failure          | 6 (6.7%)               | 9 (11.2%)              |
| Cure             | 57 (63.3%)             | 58 (72.5%)             |
| Improvement      | 27 (30.0%)             | 13 (16.3%)             |
| Success          | 84 (93.3%)             | 71 (86.8%)             |
| P*               |                        | 0.865                  |
| P**              |                        | 0.485                  |
| P                 |                        |                        |
| Postmenopausal   |                        |                        |
| Failure          | 3 (7.1%)               | 5 (13.9%)              |
| Cure             | 23 (54.8%)             | 25 (69.4%)             |
| Improvement      | 16 (38.1%)             | 6 (16.7%)              |
| Success          | 39 (92.9%)             | 31 (86.1%)             |
| Premenopausal    |                        |                        |
| Failure          | 3 (6.3%)               | 4 (9.1%)               |
| Cure             | 34 (70.8%)             | 33 (75.0%)             |
| Improvement      | 0.648                  | 0.865                  |
| Success          | 11 (22.9%)             | 7 (15.9%)              |
| P*               |                        |                        |
| P**              |                        |                        |

IIQ-7 = Incontinence Impact Questionnaire; UDI-6: Urogenital Distress Inventory-Short Form.

* = Chi-square test; p values show the comparison of the premenopausal and postmenopausal patients according to failure and cure rates.

** = Chi-square test; p values show the comparison of the premenopausal and postmenopausal patients according to failure and success rates.
The effects of menopause on TOT surgery

The 5th year of follow-up, premenopausal group had 3 patients with positive cough test, while post-menopausal group had four. The difference was not significant (p=0.419). Concerning systemic diseases, there was no difference between the 1st year and 5th year results of the groups (p=0.734 and p=0.838, respectively) (Table-3).

There was no significant difference between the postmenopausal and premenopausal groups in terms of de novo urgency, de novo UUI, dyspareunia, perineal pain, and vaginal discharge in 1st and 5th year follow-ups (p >0.05) (Table-3).

### DISCUSSION

Urinary incontinence constitutes an important sociocultural health problem with high prevalence. Considering that the quality of life has attained more importance and the average life expectancy has extended, SUI treatment will become more valuable in the coming years with the increased number of geriatric individuals.

Studies showing the effects of menopause on various surgical techniques applied in the treatment of SUI report different results. While some emphasize the negative effects of menopause, others suggest that there is no such effect. In 2010, Rechberger et al. concluded that both menopause and aging had a detrimental effect on the ultimate outcome of both retropubic and transobturator sling due to the development of textural and hormonal changes (13). The study undertaken by Polat et al. confirms this finding, they found no significant difference in the mean operation time, length of hospital stay or intraoperative and postoperative complications, but noted that the premenopausal women were more satisfied with...
### Table 3 - Comparison of the demographic characteristics, surgical outcomes and complications of the postmenopausal and premenopausal groups in terms of follow-up years.

|                        | Postoperative 1.st year (n=90) | Postoperative 5.th year (n=80) | P     | Postmenopausal n=44 (55%) | Postmenopausal n=36 (45%) | P     |
|------------------------|--------------------------------|--------------------------------|-------|---------------------------|---------------------------|-------|
| **BMI (kg/m²)**        | 27.1±4.2                       | 26.6±3.6                       | 0.370 | 27.2±4.2                  | 26.3±3.6                  | 0.234 |
| **Follow-up time (months)** | 94.8±33.1                   | 83.6±37.7                      | 0.148 | 102.3±22.5                | 95.5±25.2                 | 0.210 |
| **Operation time (min)** | 29.7±10.6                     | 29.5±9.0                       | 0.931 | 29.5±10.8                 | 29.6±9.7                  | 0.978 |
| **Hospitalization (days)** | 1.2±0.6                      | 1.1±0.3                        | 0.264 | 1.3±0.6                   | 1.1±0.3                   | 0.200 |
| **Co-morbidities**     |                                |                                | 0.838 |                            |                           |       |
| No                     | 26 (54.2%)                     | 27 (64.3%)                     | 0.734 | 24 (54.5%)                | 22 (61.1%)                |       |
| Diabetes Mellitus      | 8 (16.7%)                      | 5 (11.9%)                      |       | 7 (15.9%)                 | 5 (13.9%)                 |       |
| Hypertension           | 5 (10.4%)                      | 4 (9.5%)                       |       | 5 (11.4%)                 | 4 (11.1%)                 |       |
| Thyroid diseases       | 3 (6.3%)                       | 3 (7.1%)                       |       | 2 (4.5%)                  | 3 (8.3%)                  |       |
| COPD                   | 4 (8.3%)                       | 1 (2.4%)                       |       | 4 (9.1%)                  | 1 (2.8%)                  |       |
| **Complications**      |                                |                                | 0.172 |                            |                           |       |
| No                     | 42 (87.5%)                     | 40 (95.2%)                     | 0.156 | 40 (90.1%)                | 34 (94.4%)                |       |
| Bleeding               | 4 (8.3%)                       | 0 (0.0%)                       |       | 3 (6.8%)                  | 0 (0.0%)                  |       |
| Acute urinary retention| 2 (4.2%)                       | 0 (0.0%)                       |       | 1 (2.3%)                  | 0 (0.0%)                  |       |
| Bladder injury         | 0 (0.0%)                       | 2 (4.8%)                       |       | 0 (0.0%)                  | 2 (5.6%)                  |       |
| MMK(+)                 | 2 (4.2%)                       | 3 (7.1%)                       | 0.564 | 4 (9.1%)                  | 3 (8.3%)                  | 0.419 |
| Q tip (°)              | 16.4±13.0                      | 17.9±11.9                      | 0.571 | 19.7±16.1                 | 19.9±16.0                 | 0.955 |
| SUI (+)                | 3 (6.3%)                       | 3 (7.1%)                       | 0.542 | 4 (9.1%)                  | 5 (13.9%)                 | 0.319 |
| De-novo urgency        | 2 (4.2%)                       | 1 (2.4%)                       | 0.550 | 5 (11.4%)                 | 6 (16.7%)                 | 0.344 |
| De-novo urge incontinence | 3 (6.3%)                  | 2 (4.8%)                       | 0.564 | 5 (11.4%)                 | 6 (16.7%)                 | 0.332 |
| Recurrent UTI          | 0 (0.0%)                       | 5 (12.0%)                      | 0.039 | 0 (0.0%)                  | 5 (13.9%)                 | 0.045 |
| Dyspareunia            | 6 (12.5%)                      | 3 (7.1%)                       | 0.314 | 5 (11.4%)                 | 2 (5.6%)                  | 0.307 |
| UDI-6                  | 7.1±13.0                       | 10.7±18.1                      | 0.274 | 9.8±16.8                  | 12.8±19.8                 | 0.453 |
| IIQ-7                  | 7.6±18.7                       | 10.9±20.3                      | 0.421 | 15.1±30.3                 | 17.5±24.9                 | 0.699 |
| ICIQ-SF                | 1.8±4.6                        | 1.8±4.0                        | 0.984 | 2.9±5.9                   | 3.3±4.8                   | 0.776 |

BMI = Body mass index; DM = Diabetes Mellitus; HT = Hypertension; COPD = Chronic obstructive pulmonary disease; MMK = Marshall-Marchetti-Krantz; SUI = Stress urinary incontinence; UTI = Urinary tract infection; UDI-6 = Urogenital Distress Inventory-Short Form; IIQ-7 = Incontinence Impact Questionnaire; ICIQ-SF = International Consultation on Incontinence short-form questionnaire.
the surgery than the postmenopausal women. In addition, the improvement in the UDI-6 scores of premenopausal women was more significant (8). In contrast to these results, researchers investigating the effect of menopause on the success and failure rate of the Burch procedure examined 258 patients and observed no effect of menopause on the failure rate (14). Yasa et al. showed that TOT surgery in SUI treatment had high rates of success and patient satisfaction and a low postoperative morbidity rate in postmenopausal women aged over 65 years (15). Agarwal et al. reported that TOT surgery was more successful in premenopausal women younger than 50 years with a urethral mobility greater than 30 degrees (16). In the present study, there was no difference between the postmenopausal and premenopausal groups in terms of TOT success and fifth-year follow-up evaluations. We did not find any difference in the duration of follow-up, operation time, and hospitalization time between the two groups. According to the results of the UDI-6 and IIQ-7 questionnaires, the postmenopausal and premenopausal groups did not differ in relation to the rates of TOT failure, TOT success and clinical improvement.

Arrabal-Polo et al. calculated the total complication rate of TOT surgery as 12% in their study (17). Kaelin-Gambirasio et al. found the peroperative and early postoperative complication rate to be 9.5% (18). In our study, the peroperative and early postoperative complication rate being 7.2% confirms the safety of the TOT operation.

Richter et al. comparatively evaluated patients under 65 years (34.6% premenopausal) and over 65 years (all postmenopausal) that underwent the Burch colposuspension or pubovaginal sling for the treatment of SUI and found no difference in the complication rates (including hemorrhage) of the two groups (19). Yasa et al. did not observe any bladder perforation among the postmenopausal patients aged below and over 65 years that underwent TOT surgery due to SUI and noted no statistically significant difference between the groups concerning other complications observed, namely voiding dysfunction, vaginal erosion, de novo urgency, and suprapubic or hip pain (15). In the current study, considering the four patients with a blood loss of more than 200mL, the rate of hemorrhage was 2.8%.

Voiding difficulty is another complication that develops in the postoperative period. Urinary obstruction that occurs in the first few days may be due to edema and pain, but in the following days, specifically within 10 days, this effect is minimized and the patient is expected to perform the voiding function without difficulty (20). In the present study, transient urinary retention developed in two patients (1.8%) in the early postoperative period, and therefore the catheter remained for one week. The patients were able to spontaneously urinate after the catheter was removed. The four patients with hemorrhage and the two patients with acute urinary retention were in the premenopausal group. Bladder injury was seen in only two patients, both in the postmenopausal group. Despite the absence of a statistically significant difference between the two groups in terms of complications, the presence of hemorrhage in four and acute urinary obstruction in two premenopausal patients could be explained by congestion, blood supply and edema due to estrogen, and similarly, the two cases of bladder injury being seen in the postmenopausal group can be attributed to the reduced level of estrogen, resulting in tissue thinning and increased fragility.

Another condition that can be seen after TOT operations is de novo urgency incontinence, which was identified at a rate of 5.6% in the first year and 13.8% in the fifth year of the current study. Consistent with the report of Yasa et al., we found no difference between the postmenopausal and premenopausal groups (15).

Urinary tract infection, another complication encountered after mid-urethral sling operations, occurs at a rate of 34% in the first three months and 50% in the first year (21, 22). The prevalence of recurrent UTI is reported as 6.4% in various case series (23). In a study by Weintraub et al., the rate of UTI was found to be 21.3% after mid-urethral sling surgery. When the groups with and without infection were considered, the mean age of the infection group was greater, but without statistical significance. The menopause status was not different in these groups. The authors suggested that UTI had a linear relationship with the presence of perineal hematoma and prolonged hospitalization time (24). In our
patient groups, the rate of recurrent UTI was 5.6% in the first year and 6.3% in the fifth-year follow-up. All the patients presenting with recurrent UTI were in the postmenopausal group, and there was a statistically significant difference for the first-year and fifth-year values. As expected, the mean age of the postmenopausal group was higher than that of the premenopausal group. None of the patients with recurrent UTI had perioperative complications. We consider that the reason for detecting increased recurrent UTI in the postmenopausal group is the reduced estrogen, blood supply, and weakening of the bladder mucosal barrier.

The main limitation of this study is its retrospective design. Data about menopause status of patients was only evaluated before TOT surgery also there was no data which patients used hormonal therapy for menopause.

CONCLUSIONS

Transobturator tape surgery is an effective and reliable method according to the long-term outcomes reported in this paper. In the current study, we determined that the TOT success rates were not affected by the presence of menopause.

CONFICT OF INTEREST

None declared.

REFERENCES

1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4-20.
2. Dumoulin C, Hunter KF, Moore K, Bradley CS, Burgio KL, Hagen S, et al. Conservative management for female urinary incontinence and pelvic organ prolapse review 2013: Summary of the 5th International Consultation on Incontinence. Neurourol Urodyn. 2016;35:15-20.
3. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167-78.
4. Staskin D, Kelleher C. Committee 5A initial assessment of urinary incontinence in adult male and female patients. In: Incontinence: 5th International Consultation on Incontinence, edited by P. Abrams, S. Khoury, A. J. Wein, and L. Cardozo. Paris: ICUD-EAU 2013;361–88.
5. Delorme E. [Transobturator urethral suspension: minimvasive procedure in the treatment of stress urinary incontinence in women]. Prog Urol. 2001;11:1306-13.
6. Cardozo L, Rekers H, Tapp A, Barnick C, Shepherd A, Schussler B, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18:47-53.
7. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl 1):45-51.
8. Dursun P, Bildaci TB, Zeyneloglu HB, Kuscu E, Ayhan A. Transobturator tape operation is more effective in premenopausal women than in postmenopausal women with stress incontinence. Korean J Urol. 2011;52:612-5.
9. Karatas A, Duran B, Ozlu T, Koc O, Donmez ME, Guler A. Evaluation of treatment success in patients undergoing transobturator tape surgery. J Turk Soc Obstet Gynecol. 2014;2:115-8.
10. Cetinel B, Ozkan B, Can G. The validation study of ICIQ-SF Turkish. Turk J Urol. 2004; 30: 332-8.
11. Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. Neurourol Urodyn. 2007;26:129-33.
12. Cañete P, Ortiz E, Domingo S, Cano A. Transobturator suburethral tape in the treatment of stress urinary incontinence: efficacy and quality of life after 5 year follow-up. Maturitas. 2013;74:166-71.
13. Rechberger T, Futyma K, Jankiewicz K, Adamiak A, Bogusiewicz M, Skorupski P. Body mass index does not influence the outcome of anti-incontinence surgery among women whereas menopausal status and ageing do: a randomised trial. Int Urogynecol J. 2010;21:801-6.
14. Sun MJ, Ng SC, Tsui KP, Chang NE, Lin KC, Chen GD. Are there any predictors for failed Burch colposuspension? Taiwan J Obstet Gynecol. 2006;45:33-8.
15. Yasa C, Gungor Ugurlucan F, Dural O, Yumru H, Gunaydin C, Yalcin O. Transobturator Tape Operation for the Treatment of Stress Urinary Incontinence in Postmenopausal Women Aged Over 65 Years. Low Urin Tract Symptoms. 2018;10:153-157.
16. Agarwal A, Patnaik P, Shaw D, Rathee V, Khan SW, Jain M, et al. Influence of Demographic and Clinical Factors on Surgical Outcomes of the Transobturator Tape Procedure in Patients with Stress Urinary Incontinence. Curr Urol. 2015;8:126-32.
17. Arrabal-Polo MÁ, Palao-Yago F, Zuluaga-Gómez A, López-León VM, Merino-Salas S, Lahoz-García C, et al. Complications from the placement of a tension-free suburethral sling using the transobturator and retropubic methods for treatment of female urinary incontinence. Urol Int. 2012;89:97-102.

18. Kaelin-Gambirasio I, Jacob S, Boulvain M, Dubuisson JB, Dällenbach P. Complications associated with transobturator sling procedures: analysis of 233 consecutive cases with a 27 months follow-up. BMC Womens Health. 2009;9:28.

19. Richter HE, Goode PS, Brubaker L, Zyczynski H, Stoddard AM, Dandreo KJ, et al. Two-year outcomes after surgery for stress urinary incontinence in older compared with younger women. Obstet Gynecol. 2008;112:621-9.

20. Zaragoza MR. Expanded indications for the pubovaginal sling: treatment of type 2 or 3 stress incontinence. J Urol. 1996;156:1620-2.

21. Anger JT, Litwin MS, Wang Q, Pashos CL, Rodríguez LV. Complications of sling surgery among female Medicare beneficiaries. Obstet Gynecol. 2007;109:707-14.

22. Suskind AM, Clemens JQ, Dunn RL, Zhang Y, Stoffel JT, Hollenbeck BK. Effectiveness of mesh compared with nonmesh sling surgery in Medicare beneficiaries. Obstet Gynecol. 2013;122:546-52.

23. Groutz A, Levin I, Gold R, Pauzner D, Lessing JB, Gordon D. “Inside-out” transobturator tension-free vaginal tape for management of occult stress urinary incontinence in women undergoing pelvic organ prolapse repair. Urology. 2010;76:1358-61.

24. Weintraub AY, Reuven Y, Paz-Levy D, Yohay Z, Idan I, Elharar D, et al. Prevalence and risk factors for urinary tract infection up to one year following midurethral sling incontinence surgery. Eur J Obstet Gynecol Reprod Biol. 2018;222:146-150.

Correspondence address:
Mehmet Oguz Sahin, MD
Department of Urology, Manisa State Hospital
Manisa, Turkey
Telephone: + 90 505 246-7376
E-mail: urologoguz@yahoo.com